| CTRI Number |
CTRI/2024/11/077199 [Registered on: 21/11/2024] Trial Registered Prospectively |
| Last Modified On: |
20/11/2024 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug Unani |
| Study Design |
Randomized, Parallel Group, Active Controlled Trial |
|
Public Title of Study
|
Efficacy of a Unani Formulation in the Management of Diabetes Mellitus |
|
Scientific Title of Study
|
A Clinical Study to Evaluate the Efficacy and Safety of a Unani Formulation in the
Management of Ziabetus Shakari (Diabetes Mellitus): A Randomized, Active
Controlled, Parallel Group Clinical Trial |
| Trial Acronym |
Nil |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Saba Khan |
| Designation |
Pg Scholar |
| Affiliation |
State Takmeel ut Tib College and Hospital Lucknow |
| Address |
Department of Moalajat
State Takmeel ut Tib College and Hospital Near Ramabai Raily Sthal Aurangabaad Tiraha Lucknow India 226002
Lucknow UTTAR PRADESH 226002 India |
| Phone |
7217813082 |
| Fax |
|
| Email |
khansabajamia2@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Abdul Qadir |
| Designation |
Associate Professor |
| Affiliation |
State Takmeel ut Tib College and Hospital Lucknow |
| Address |
Department of Moalajat
State Takmeel ut Tib College and Hospital Near Ramabai Raily Sthal Bijnor Road Aurangabad Tiraha Lucknow India 226002
Lucknow UTTAR PRADESH 226002 India |
| Phone |
9415757169 |
| Fax |
|
| Email |
aq.ayaz5775@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Abdul Qadir |
| Designation |
Associate Professor |
| Affiliation |
State Takmeel ut Tib College and Hospital Lucknow |
| Address |
Department of Moalajat
State Takmeel ut Tib College and Hospital Near Ramabai Raily Sthal Bijnor Road Aurangabad Tiraha Lucknow India 226002
Lucknow UTTAR PRADESH 226002 India |
| Phone |
9415757169 |
| Fax |
|
| Email |
aq.ayaz5775@gmail.com |
|
|
Source of Monetary or Material Support
|
| State Takmeel ut Tib College and Hospital Near Ramabai Raily Sthal Aurangabad Tiraha Lucknow India 226002 |
|
|
Primary Sponsor
|
| Name |
Dr Saba Khan |
| Address |
Department of Moalajat
State Takmeel ut Tib College and Hospital Near Ramabai Raily Sthal Aurangabaad Tiraha Lucknow India 226002 |
| Type of Sponsor |
Other [Self] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Saba Khan |
State Takmeel ut Tib College and Hospital |
OPD Department of Moalajat
Near Ramabai Raily Sthal Bijnor Road Aurangabad Tiraha Lucknow 226002 Lucknow UTTAR PRADESH |
7217813082
khansabajamia2@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethical Committee for Biomedical Research |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: E119||Type 2 diabetes mellitus without complications, (2) ICD-10 Condition: E119||Type 2 diabetes mellitus without complications, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
Tab Metformin |
Tab Metformin
Dosage Form: Tablets
Dose: 500mg
Frequency: Twice a Day half hour before meals
Route of Administration: Orally
Duration: 60 Days |
| Intervention |
Unani Polyherbal Formulation |
Unani Polyherbal Formulation
Dosage Form: Safuf (Powder)
Dose: 6gm
Frequency: Twice a Day half hour before meals
Route of Administration: Orally
Duration: 60 Days |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
60.00 Year(s) |
| Gender |
Both |
| Details |
Patients age group 18 to 60 years old of any gender.
Fasting Plasma Glucose levels between 126mg/dl and 150 mg/dl or Postparandial Plasma Glucose levels ranging from 200 mg/dl to 250 mg/dl 2 hour after ingestion of 75mg of glucose in 300ml of water or HbA1C levels ranging 6.5% to 10%.
Presence of symptoms and signs of diabetes mellitus type2. |
|
| ExclusionCriteria |
| Details |
Patients having any deliberating systemic disease.
Patients on insulin therapy and suffering from diabetes mellitus type-1.
Patients with complications of Diabetes mellitus type2
Patients suffering from thyroid function disorders.
Pregnant and lactating women.
Known case of immunocompromised states (HIC, AIDS etc) or malignancies. |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
1 Fasting and PP glucose level
2 HBA1c level
3 Improvement in symptoms and signs on VAS Scale (0-10) |
Baseline
2 Weeks
4 Weeks
6 Weeks
8 Weeks |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
1 Haemogram
2 Lft
3 Kft
4 Lipid Profile
5 Urine RM |
Baseline
2 Weeks
4 Weeks
6 Weeks
8 Weeks |
|
|
Target Sample Size
|
Total Sample Size="60" Sample Size from India="60"
Final Enrollment numbers achieved (Total)= "60"
Final Enrollment numbers achieved (India)="60" |
|
Phase of Trial
|
Phase 2/ Phase 3 |
|
Date of First Enrollment (India)
|
01/12/2024 |
| Date of Study Completion (India) |
01/06/2025 |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Date Missing |
|
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Completed |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Dhayabitus Shakari (Diabetes mellitus) is a clinical syndrome of multiple etiologies characterized by an increase in plasma blood glucose (hyperglycemia) with disturbances of carbohydrate, fat, and protein metabolism. There are two main types of diabetes mellitus: type 1 and type 2. Type 1 diabetes is generally considered to result from autoimmune destruction of insulin-producing cells (β cells) in the pancreas, leading to marked insulin deficiency, whereas type 2 diabetes is characterized by reduced sensitivity to the action of insulin and an inability to produce sufficient insulin to overcome ‘insulin resistance’. Millions of individuals are affected by diabetes mellitus type II , which is the most common and rapidly progressing serious non-communicable disease in the world. Diabetes that has not been properly diagnosed results in various complications. Chronic hyperglycemia is responsible for diabetes-specific microvascular complications affecting the eyes (retinopathy), kidneys (nephropathy), and feet (neuropathy)1 and macrovascular complications include cardiovascular, cerebrovascular, and peripheral vascular disease.
The prevalence of diabetes has reached epidemic levels. Diabetes mellitus is rapidly becoming one of the most common non-communicable diseases. WHO reports diabetes mellitus as the ninth leading cause of death globally, accounting for 74% of global deaths in 2019. The International Diabetes Federation (IDF) reports that diabetes kills one person every seven seconds and kills about 3.2 million people every year worldwide. In India, there were 31.7 million individuals with diabetes overall in 2000, and 79.4 million are project to have the disease by 2030. Between 2000 and 2030, it is expected that the number of urban diabetics in emerging nations will double. Diabetes is predicted to kill 592 million people by 2035.
In the Unani system of medicine, physicians used various names for Dhayabitus, including Moattasha, Atsha, Zalaqul Kulliya, Dolab, Dawwarah, Barkar, Barkarya, and Qaramees. The various facts of diabetes mellitus have been well documented and addressed in unani classical Unani texts. Dhayabitus is a kidney disease, and it has been described as the patient passing the urine promptly just after taking water. Ibne Sina termed it Zalaqul Kulliya. The etiopathogenesis of Dhayabitus Shakari in unani literature is based on Sue mizaj gurda (derangement in temperament), Zauf-e-kulliya (weakness of kidney) and Structural deviation (Ittasa-e- gurda). Many antidiabetic drugs found in Unani treasures are of natural origin. They are not only effective and potent in controlling glucose levels but also equally safe and less harmful than their modern counterparts. Various single (mufrad) and compound (murakkab) antidiabetic drugs like Maghze jamun, Methi, Satte gilo, Gulnaar, Tabasheer, Gil-e-armani, Tukhm-e- konch and Qurs-e- Kafoor, Qurs-e- Tabasheer, Qurs-e- Dhayabitus, Qurs-e-Gulnaar etc. are mentioned in unani literature.
Keeping the above facts in mind, the present study entitled "A Clinical Study to Evaluate the Efficacy and Safety of a Unani Formulation in the management of Dhayabitus Shakari (Diabetes Mellitus): A Randomized, Active Controlled, Parallel Group Clinical Trial†has been designed. A polyherbal unani formulation in powdered form containing Tabasheer (Bambusa arundinacea), Gulnaar (Punica granatum), Gile Armini (Armenia Bole), Tukhm Khurfa (Portulaca oleracea) and Tukhm Kaahu (Lactuca sativa) is selected to evaluate its efficacy and safety in the management of Dhayabitus Shakari Qism Sani (Diabetes Mellitus type 2).
|